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Sickle cell anemia (SCA) is a common hemolytic disorder caused by a gene mutation in the β-globin subunit of hemoglobin
(Hb) and aﬀects millions of people. The intravascular hemolysis releases excessive amount of extracellular hemoglobin (ECHb)
into plasma that causes many cellular dysfunctions in patients with SCA. ECHb scavenges NO which promotes crisis events such
as vasoconstriction, thrombosis and hypercoagulation. ECHb and its degradation product, heme, are known to cause oxidative
damage to the vessel wall and stimulate the expression of adhesive protein ligands on vascular endothelium. Our study shows
that ECHb binds potently to VWF—largest multimeric glycoprotein in circulation—through the A2-domain, and signiﬁcantly
inhibits its cleavage by the metalloprotease ADAMTS13. Furthermore, a subpopulation of VWF multimers bound to ECHb exists
in signiﬁcant amount, accounting for about 14% of total plasma VWF, in SCD patients. The Hb-bound VWF multimers are
resistant to ADAMTS13, and are hyperactive in aggregating platelets. Thus, the data suggest that Hb-bound VWF multimers are
ultralarge and hyperactive because they are resistant to the protease. The Hb-bound VWF multimers are elevated parallely with
the level of ECHb in patients’ plasma, and is associated with the pathogenesis of thrombosis and vascular occlusion in SCA.
1.Introduction
Sickle cell anemia (SCA) is a hemolytic disorder ﬁrst de-
scribed by Herrick in1910 [1]. In 1949, Pauling and his team
ﬁrst demonstrated the molecular basis of SCA, showing that
the disease is caused by a small diﬀerence in the molecular
structure of hemoglobin, an oxygen-carrying protein in
plasma [2]. In 1957, Ingram discovered that the disease was
causedbyasingle amino acid substitution(Glutamicacid →
Valine) in the β-globin subunit of hemoglobin [3].
Sickle cell anemia aﬀects millions of people worldwide
and is associated with signiﬁcant morbidity and mortality.
An estimated 2% of the world’s population carries genes
responsible for SCA. Each year about 300,000 infants are
born with SCA, including more than 200,000 cases in Africa
[4]. More than 33% of deaths in SCA patients are caused by
vascular occlusions and related crises, such as strokes and
transient ischemic attacks [5, 6]. It is estimated that stroke
alone results in 20% mortality in such patients between the
ages of 5 to 10 years, with 70% of those patients having a
motor deﬁcit and signiﬁcant neurocognitive deﬁcits; 70%
have a recurrent stroke within the next 3 years [7, 8].
It is known that under hypoxic conditions, deoxy-
genation triggers a hydrophobic interaction between the
mutated hemoglobin (HbS)molecules, resulting in the poly-
merization of HbS and sickling of the RBCs. Sickling
alters the cell membrane properties, which reduce cellular
ﬂexibility and lead to unusual cell adherence to vascular
endothelium [5, 6]. Studies further suggest that sickling
alters the RBCs’membrane propertiesincluding asigniﬁcant
expression/exposure of diﬀerent adhesive molecules, which
mediate the adhesion of sickle RBCs to endothelium and
subendothelial matrix [9–16]. Previous studies, including
our own, suggest that exposure of a membrane lipid such as
sulfated glycosphingolipid or sulfatide on sickle RBCs pro-
motessicklecelladhesiontoendothelialligands(suchasαvβ3
and ULVWF) and subendothelial matrix proteins (such as
VWF, TSP, LN and FN) [17–19]. Furthermore, the data also2 Anemia
demonstrate that sickle RBCs express a signiﬁcant quantity
of phosphatidylserine (PS) on the cell surface and promote
the adhesion to the endothelium through binding to αvβ3
[20]. Besides the increase of expression/exposure of adhesive
molecules on sickle RBCs, which is associated with increased
celladhesion tothevesselwall, sicklingalsocauses therelease
of excessive extracellular hemoglobin (ECHb) into plasma
from the sickle RBCs during intravascular hemolysis.
2.ExtracellularHemoglobin Causes
CellularDysfunctions
Hemoglobin is a heme-containing globular protein in RBCs
that can deliver oxygen and remove carbon dioxide to/from
cells and tissues. In hemolytic conditions such as SCA,
RBCs release an excessive amount of ECHb into plasma,
ranging from 20–330μg/mL in patients, which can exceed
410μg/mLduring vasoocclusivecrisis[21–23].Uponrelease,
ECHbformsacomplexwiththehemoglobin-scavenger,hap-
toglobin, in circulation and is cleared by binding to CD163
on macrophage or leukocyte surfaces [24, 25]. Haptoglobin
can bind approximately 70–150μg/mL of ECHb depending
on the haptoglobin allotype [26]. Once the capacity of
haptoglobin is exceeded, an elevated level of ECHb accu-
mulates in plasma, causing many cellular dysfunctions. In
severe hemolytic diseases such as PNH and SCA, serum hap-
toglobin is typically undetectable [27].
The accumulation of excessive ECHb in plasma intensi-
ﬁes the consumption of endogenous nitric oxide (NO), re-
sulting in several cellular dysfunctions such as vasoconstric-
tion and systemic and pulmonary hypertension in patients
with hemolytic disorders including SCA. It has been shown
that the ECHb could scavenge NO, an important endoge-
nous vasodilator, and impair the vasodilatory response to
infusions of the direct-acting NO donor to patients [28].
Consistently, patients with plasma ECHb levels higher than
100μg/ml have shown an 80% reduction in NO-dependent
bloodﬂowresponses [28].Otherin vivo studies further show
that nitroglycerin-induced vasodilation is impaired in SCA
patients [29] and the diminished vasomotor response to NO
donors is observed in transgenic SCA mice [30].
Excessive ECHbalso causesothercellulardysfunctions in
SCA. The elevated ECHb in patients’ plasma impairs renal
function. Plasma ECHb is normally ﬁltered through the
glomerulus and actively reabsorbed in proximal tubule cells
where it is catabolized with release of iron in the form of
hemosiderin. When the capacity of kidney’s reabsorption
is exceeded, crises events such as renal dysfunction and
failure occur [31]. Second, excessive plasma ECHb may also
contribute to platelet activation and thrombosis. An in vitro
experiment shows that the addition of ECHb to human
serum at concentrations of 0.2–2mg/mL dose-dependently
inhibits the activity of metalloprotease ADAMTS13, an
enzyme critical in limiting platelet thrombus formation
[32]. It is also suggested that the major untoward eﬀects of
ECHb on platelet function are most likely mediated by NO
scavenging. NO has been shown to inhibit platelet aggre-
gation, induce disaggregation of aggregated platelets, and
inhibit platelet adhesion through increasing cyclic guanine
monophosphate (cGMP) levels [33]. In addition, NO is
also known to interact with components of the coagulation
cascade (such as factor XIII and ﬁbrin) to downregulate clot
formation [34, 35]. Thus, NO scavenging by ECHb or the




Our investigation shows that excessive ECHb signiﬁcantly
inhibits the cleavage of VWF [23], a multimeric protein in
circulation that normally serves in hemostatic functions.
However, under pathophysiological conditions such as in
SCA patients, the hyperactive VWF multimers play a signiﬁ-
cant role in cell adhesion and prothrombotic complications.
This is particularly signiﬁcant given that VWF multimers
secreted from endothelial cells or platelets may accumulate
as ultralarge (UL) multimers in plasma if not properly
cleaved by the metalloprotease ADAMTS13. As evident in
SCA, inﬂamed endothelium constitutively secretes ULVWF,
maintaining a high VWF antigen level in plasma. Studies,
includingourown,suggestthatelevatedVWFlevels,particu-
larly ultralarge multimers, exist in SCA patients’ plasma, and
are associated with increased sickle cell and platelet adhesion
to vascular endothelium [23, 36–39]. Several studies have
also suggested that ULVWF multimers contain all the
determinants necessary for blood cells (including platelets,
sickled-RBCs, and neutrophils) to tether and stably adhere
to endothelium spontaneously [40–42].
Considering the implicated role of VWF in SCD patho-
physiology, we have investigated the function of the plasma
metalloprotease ADAMTS13 that determines the length and
activity of VWF. Though SCD patients have an elevated level
of higher molecular weight or ultralarge VWF multimers in
plasma than normal, they have a very mild [23]o rn o[ 36]
deﬁciency in ADAMTS13 activity. This is important given
that ULVWF multimers freshly secreted from endothelial
cells are accumulated in plasma due to impaired cleav-
age by ADAMTS13, as seen in patients with thrombotic
thrombocytopenicpurpura (TTP). SevereTTP patientshave
very low ADAMTS13 activity (<5% of normal) caused by
a genetic mean or autoantibody inhibition, resulting in the
accumulation of ULVWF multimers and the development
of thrombotic microangiopathy [43–45]. We therefore sug-
gested that such a mild deﬁciency in ADAMTS13 in SCD
patients (70% of normal) is probably insuﬃcient to cause
any similar eﬀects on the VWF axis. Consistent with that
notion, we have shown that ECHb does interact with VWF
to inhibit its cleavage by ADAMTS13, and the mechanism
is independent of the metalloprotease activity [23]. We have
further demonstrated that ECHb binds to the ADAMTS13
cleavage site on the A2 domain of VWF multimers to block
its cleavage by the metalloprotease. The study shows that
t h ep r e s e n c eo f1 0 0 μg/mL of ECHb in buﬀer completely
inhibited the VWF cleavage by ADAMTS13 under physio-














































































Figure 1: Hb-bound VWF multimers are prevalent in SCD patients and are hyperactive. (a): the VWF was puriﬁed from plasma (1mL)
of SCD patients or normal individuals by a Superose gel ﬁltration column. The 1st protein peak (at 280nm UV) was collected for VWF.
Further, the Hb-bound VWFwasisolatedfrom above VWFfraction using an Ni-NTA aﬃnitycolumn.The VWF antigen levelwasmeasured
using a commercial kit. The Hb VWF multimers existed as about 14% of total VWF in patients compared to only about 3.5% in normals
(n = 5). (b): the ristocetin cofactor VWF activity assay shows that the Hb-bound VWF multimers are 35% more activity than the Hb-free

















Figure 2: The schematic diagram shows that upon activation of the vascular endothelium, ultralarge VWF is released and is cleaved by
ADAMTS13 to smaller fragments that circulate in plasma as an inactive form. Under pathophysiological conditions such as SCA, excessive
extracellularHbblocksthecleavageofasubpopulationofVWFmultimers.TheuncleavedHb-bound VWFmultimersaccumulateinplasma,
which are hyperactive in binding to platelets or sickled/fragmented-RBCs to promote cell adhesion and events such as thrombosis and
vascular occlusion.
have elevatedECHb in plasma, as estimated up to 410μg/mL
during their vasoocclusive crisis [21–23], we speculated that
excessive ECHb could impair VWF cleavage by ADAMTS13
in vivo and promote accumulation of hyperactive VWF
multimers in patients’ plasma. Accordingly, we have isolated
a subpopulation of VWF multimers from plasma that are
bound to ECHb [46]. The Hb-bound VWF multimers
exist in SCA patients’ plasma, accounting for 14% of total
plasma VWF, which is about 4-folds more than normal
individuals (Figure 1). Though the interaction between4 Anemia
ECHb and VWF and their relationship in vivo is still not
clearly un-derstood, our data have shown that increased Hb-
bound VWF multimers parallely coexisted with the high
ECHb level in patients’ plasma (mean ± SE ∼ 263.8 ±
41.7 (SCA) versus 46.2 ± 9.6 (Normal, n = 5)) [46].
Furthermore, we have observed that ECHb preferentially
binds to the endothelial cell-puriﬁed ULVWF over the
plasma-puriﬁed VWF multimers. It is possible that ECHb
binds to ULVWF multimers that are freshly released into
plasma and have their A2-domains exposed. As evident,
the A2-domain of ULVWF multimers has unique features
such as a lack of protection by disulﬁde bonds within
VWF and low resistance to unfolding that help the domain
to be exposed easily [47]. When exposed to intravascular
hydrodynamic shear forces, the tensile force on the ULVWF
multimers increases by the square of the multimer length,
providing an eﬃcient mechanism for unfolding of the A2
domain on ULVWF [48]. The similar mechanism in which
shear force induced exposure of the A2 domain in freshly
released (UL)VWF multimers could probably facilitate the
binding of ECHb to VWF, which prevents the cleavage
of ULVWF multimers by ADAMTS13. As expected, we
found that Hb-bound VWF multimers are 30–35% more
adhesive to platelets and subendothelial matrix collagen and
less cleavable by ADAMTS13 compared to their Hb-free
counterparts [46].
We have speculated that elevated plasma Hb-bound
VWF, parallely with increased ECHb, might play an impor-
tantrole in theculmination ofbloodcell (includingplatelets,
sickle RBCs, and neutrophils) adhesion to vascular endothe-
liumand developmentofrelated criseseventssuch asthrom-
bosis, thromboembolism, ischemic strokes, and myocardial
infarctions in patients with SCA.This mechanism is not only
limited to SCA, but also occurs in other hemolytic disorders
including thalassemia, and hemolytic uremic syndrome.
This mechanism is shown through a schematic diagram in
Figure 2.
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